- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04692051
A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
December 29, 2020 updated by: Xianglin Yuan, Huazhong University of Science and Technology
It is a trial to compare the efficacy and safety of Nab-paclitaxel plus Cisplatin vs Gemcitabine plus Cispatin as first line chemotherapy in advanced biliary tract cancer.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Liang Zhuang, professor
- Phone Number: +8613006325115
- Email: mrzhuangliang@126.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Tongji Hospital, Tongji Medical college, Huazhong University of Science and Technology
-
Contact:
- Liang Zhuang, professor
- Phone Number: +8613006325115
- Email: mrzhuangliang@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged 18 to 70 years;
- Diagnosis of unresectable or recurrent or metastatic biliary tract cancer (Ampulla of Vater, gallbladder, intra or extra-hepatic biliary ducts);
- Adequate bone marrow, liver and kidney function: absdute neutrophil count (ANC) ≥ 1.5 x 10^9/L, platelet count (PLT) ≥75 x 10^9/L, hemoglobin (HB) ≥ 75 g/L, White blood cell(WBC) ≥ 3.0 x 10^9/L, no bleeding symptoms or bleeding tendency; Total bilirubin (TBIL) ≤ 3 x upper limit of normal range (ULN), alanine glutamate transaminase (ALT) and glutamate transaminase (AST) ≤ 5 x upper limit of normal range (ULN); creatinine(Cr) ≤ 1.5 x upper limit of normal range(ULN) or creatinine clearance rate(CCR)≥ 45ml/min;
- At least one measurable lesion;
- Karnofsky Performance Status(KPS) ≥ 70;
- Estimated life expectancy of at least 3 months;
- Resolution of all acute clinical toxic effects of any prior treatment to grade ≤ 1, with the exception of alopecia;
- Be able to understand and willingness to sign IRB-approved informed consent; (If the patient cannot sign the informed consent due to consciousness disorder, upper limbs paralysis or inability to write, the legal representative shall sign the informed consent on behalf of the patient).
Exclusion Criteria:
- Ongoing uncontrolled infections, or have received systemic antibiotic therapy within 72 hours prior to registration;
- Myeloproliferative disorder or any other hematopoietic function disorder;
- Have an untreated second malignancy or brain metastasis;
- Allergic to the chemotherapy drugs of this protocol;
- Unable to cooperate due to neurologic diseases or psychiatric illness;
- Pregnant or lactating female patients; Women of child-bearing age who refuse to accept contraceptive measures;
- Have other significant medical illness, for example,active tuberculosis, active pneumonia, uncorrected electrolyte disturbance, uncontrolled tumor associated pain, uncontrolled hydrothorax or seroperitoneum and so on;
- Patients need to receive other antitumor therapy at the same time;
- Have received any other experimental treatment or participated in another interventional clinical trial within 30 days prior to registration;
- Any other situation that the researcher considered patients are unsuitable for the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nab-paclitaxel + Cisplatin
Patients in this arm receive chemotherapy with Nab-paclitaxel plus Cisplatin
|
Nab-paclitaxel 125mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
|
Active Comparator: Gemcitabine + Cisplatin
Patients in this arm receive chemotherapy with Gemcitabine plus Cisplatin
|
Gemcitabine1000mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: up to 3 years
|
PFS is defined as time from the start of treatment to progression of disease or death.
|
up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: up to 3 years
|
The rate of participants that achieve either a complete response (CR) or a partial response (PR).
|
up to 3 years
|
OS
Time Frame: up to 3 years
|
Overall survival is defined as time from the start of treatment until death due to any reason.
|
up to 3 years
|
TTP
Time Frame: up to 3 years
|
Time to progress is defined as time from randomized grouping to objective progression of tumors.
|
up to 3 years
|
AEs
Time Frame: up to 3 years
|
Adverse reactions refer to the occurrence and development of diseases in the process of using drugs according to normal usage and dosage to prevent, diagnose or treat diseases.Adverse reactions unrelated to the purpose of treatment.
|
up to 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2019
Primary Completion (Anticipated)
March 1, 2021
Study Completion (Anticipated)
September 1, 2021
Study Registration Dates
First Submitted
December 29, 2020
First Submitted That Met QC Criteria
December 29, 2020
First Posted (Actual)
December 31, 2020
Study Record Updates
Last Update Posted (Actual)
December 31, 2020
Last Update Submitted That Met QC Criteria
December 29, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Digestive System Neoplasms
- Biliary Tract Diseases
- Biliary Tract Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Gemcitabine
- Paclitaxel
- Cisplatin
Other Study ID Numbers
- CSPC-KAL-BTC-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biliary Tract Cancer
-
Sun Yat-sen UniversityJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerChina
-
Gyeongsang National University HospitalSamsung Medical Center; Dong-A University; Chung-Ang UniversityTerminatedMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerKorea, Republic of
-
Hospital de Cancer de Barretos - Fundacao Pio XIIUnknown
-
Fudan UniversityRecruitingAdvanced Biliary Tract CancerChina
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingAdvanced Biliary Tract CancerChina
-
Tianjin Medical University Cancer Institute and...RecruitingResectable Biliary Tract CancerChina
-
University of Kansas Medical CenterRecruitingAdvanced Biliary Tract CancerUnited States
-
Peking Union Medical College HospitalShanghai Junshi Bioscience Co., Ltd.RecruitingAdvanced Biliary Tract CancerChina
-
Georgetown UniversityIpsenRecruitingAdvanced Biliary Tract CancerUnited States
-
Seoul National University HospitalBeiGeneActive, not recruitingAdvanced Biliary Tract CancerKorea, Republic of
Clinical Trials on Nab-paclitaxel + Cisplatin
-
Fudan UniversityUnknownAdvanced Pancreatic CancerChina
-
Henan Provincial People's HospitalCSPC Ouyi Pharmaceutical Co., Ltd.RecruitingAdvanced Biliary Tract CancersChina
-
Peking University Third HospitalUnknownCervical CancerChina
-
Jun GuoNot yet recruiting
-
Hebei Medical University Fourth HospitalRecruitingEsophageal Squamous Cell CarcinomaChina
-
The First Affiliated Hospital of Zhengzhou UniversityRecruitingAdvanced Biliary Tract CancerChina
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.RecruitingHead and Neck Squamous Cell CarcinomaChina
-
UNC Lineberger Comprehensive Cancer CenterTerminatedStage IIIA Non-Small Cell Lung CancerUnited States
-
Fudan UniversityActive, not recruitingTNBC - Triple-Negative Breast CancerChina
-
Fudan UniversityRecruiting